Dr Chiara Herzog was honored with the "AGO - Young Scientist Award" for the scientific basis of the WID®-easy Test

The AGO – Arbeitsgemeinschaft Onkologie (“Oncology Working Group”) – of the Austrian Society of Gynaecology and Obstetrics (OEGGG) presented this year’s Young Scientist Award to Dr Chiara Herzog, PhD, at its 2024 annual conference in Salzburg.

She was awarded the prize for her significant contribution to the studies published in the Journal of Clinical Oncology, the International Journal of Cancer and THE LANCET Oncology in 2022 and 2023. These publications describe the development of the WID®-qEC test for the epigenetic early detection of endometrial cancer and its validation in seven settings in 1221 patients, including 273 cancer cases.

In March 2024, the WID®-qEC test was launched by the Tyrolpath diagnostic laboratory in Austria under the brand name “WID®-easy Test“.

Real-life comparison to the state-of-the-art

The study published in THE LANCET Oncology was a prospective study conducted to compare the performance of the WID-qEC test with the standard procedure in the United Kingdom. The study took place at UCL-Hospital in London.

400 women aged 45 years and older with peri- or postmenopausal abnormal bleeding participated in the study.

The WID-qEC test reduces the number of women who need surgical diagnostic procedures such as hysteroscopy and curettage, even though they do not have cancer, by 87% compared to the standard procedure in the UK and by 95% compared to the standard procedure in Germany, Switzerland and Austria.

The WID-qEC test speeds up diagnosis in women with symptoms of endometrial cancer, leading to better outcomes and healthcare cost savings.